As Medicare Part D plans considered their formularies, the concern was that the value of Aricept and its impact was not fully understood by formulary decision-makers and that, as a result, plans might implement prior authorizations. Eisai provided this set of tools to their account managers to help them demonstrate the prevalence of the condition, its under-appreciated costs, its impact on the management of of other common chronic conditions, and the value of treatment with Aricept. A visaid enabled the account manager to communicate key messages in a one-on-one meeting. Software tool projected the prevalence of mild, moderate, and severe AD in the plan and then generated a customized presentation for the plan.